17th Oct 2013 08:41
LONDON (Alliance News) - Dechra Pharmaceuticals PLC Thursday said that its trading in the first quarter ended September 30 had been in line with expectations as growth in its core products in the EU and USA were offset by the phasing of export sales and issues with its Animax supply chain in the US.
The pharmaceuticals company said that revenue from its continuing operations for the quarter had been around 5% ahead of the previous year. Revenues from the company's European segment increased by around 6%, although US revenues were down around 5%.
Shares in Dechra were trading down 5.7% at 689.28 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
DPH.L